Capabilities
Businesses adopting artificial intelligence and machine learning technologies and the companies developing them turn to us to navigate regulatory complexities, potential liabilities, and transactional considerations they face on the path to realizing AI’s tremendous potential.
We bring together our extensive technical backgrounds and broad range of subject matter experience to help them:
Our Digital Health lawyers are advising life sciences and healthcare companies as they adopt and develop AI tools and technologies in their businesses and in the products they deliver—from digital diagnostics to digital therapeutic medical devices to medical robotics.
King & Spalding offers deep fintech industry and AI credentials to provide comprehensive legal advice to emerging and established fintech businesses, financial services firms, and PE/VC investors.
Our lawyers are at the forefront of guiding start-ups and emerging growth companies who are developing generative AI platforms and applications and the investors in such technologies.
January 31, 2025
Full Steam Ahead: Unpacking President Trump’s Executive Orders Impacting Federal Contractors
January 30, 2025
Department of Commerce Issues Export Controls on Advanced Computing Chips and Artificial Intelligence Models
January 23, 2025
Biden Administration’s Eleventh-Hour Executive Order Imposes New Software Requirements on Companies
January 20, 2025
K&S advises ServiceNow on its acquisition of software developer Cuein
January 15, 2025
Lauren Roth, former U.S. Food and Drug Administration Associate Commissioner for Policy, joins the firm’s FDA and Life Sciences team in Washington, D.C.
January 15, 2025
Lauren Roth, Former Leader of FDA’s Office of Policy, Joins King & Spalding’s FDA and Life Sciences Team